Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model ; volume:14 ; number:1 ; day:2 ; month:1 ; year:2024 ; pages:1-8 ; date:12.2024
Scientific reports ; 14, Heft 1 (2.1.2024), 1-8, 12.2024
- Creator
-
Abdoli, Asghar
Jamshidi, Hamidreza
Taqavian, Mohammad
Baghal, Mehdi Lari
Jalili, Hasan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-50822-w
- URN
-
urn:nbn:de:101:1-2024031811302411074845
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Abdoli, Asghar
- Jamshidi, Hamidreza
- Taqavian, Mohammad
- Baghal, Mehdi Lari
- Jalili, Hasan
- SpringerLink (Online service)
Other Objects (12)
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Technetium abundance in Omicron Ceti
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Technetium abundance in Omicron Ceti
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Technetium abundance in Omicron Ceti
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia